hC Bioscience, Inc
HC Bioscience is a pioneer in developing minimally engineered tRNA to edit proteins in a gene agnostic way.
Our protein editing approach corrects disease-causing mutations without altering DNA or mRNA, with one therapeutic tRNA having the potential to address a broad spectrum of genetically driven diseases.
We have two distinct DNA-based non-viral formulations for addressing both liver-targeted and extra-hepatic indications. We expect to be in the clinic with our lead program, Hemophilia A, next year.
